Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
02:51pm, Wednesday, 12'th Feb 2025
Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.
Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow
09:04am, Wednesday, 12'th Feb 2025
Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. EXEL's 2025 total revenue guidance is flat at $2.15B-$2.25B, although that doesn't model
Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript
08:24pm, Tuesday, 11'th Feb 2025
Exelixis, Inc. (NASDAQ:EXEL ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs & Investor Relations Mike Morr
Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
07:01pm, Tuesday, 11'th Feb 2025
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compa
Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates
06:26pm, Tuesday, 11'th Feb 2025
Exelixis (EXEL) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.33 per share a year ago.
Exelixis Posts 63.7% Profit Surge
05:16pm, Tuesday, 11'th Feb 2025
Exelixis (EXEL -2.06%), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and earnings.
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 11'th Feb 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key cor
2 Stocks to Buy With Less Than $40
09:00am, Monday, 10'th Feb 2025
Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, investors can acquire shares of companies whose long-term prospects look excit
EXEL or TECH: Which Is the Better Value Stock Right Now?
12:40pm, Thursday, 06'th Feb 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to v
4 PEG-Based GARP Stocks to Stay Ahead in Uncertain Markets
11:36am, Thursday, 06'th Feb 2025
Here are four PEG-driven GARP stocks, PPC, EXEL, SYF and UAL, which qualify our screening criteria.
Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics
10:21am, Thursday, 06'th Feb 2025
Evaluate the expected performance of Exelixis (EXEL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metric
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:46am, Wednesday, 29'th Jan 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
11:05am, Tuesday, 28'th Jan 2025
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform
01:40pm, Monday, 27'th Jan 2025
EXEL loses 5% after Oppenheimer downgrades its rating to Perform from Outperform on concerns about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the a
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination wi
